Billing and Coding: Skin Substitutes Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers

Covers application of skin substitute grafts (non‑autologous human, xenograft, cellular/acellular and sheet-forming biological products) for diabetic foot and venous leg ulcers when meeting LCD L39764 reasonable-and-necessary criteria, and excludes non‑graft wound dressings and injected skin substitutes as separately billable (these are bundled/not payable). Key requirements: follow the LCD for medical necessity, do not report graft application codes with non‑graft or injected products, and use the appropriate Medicare modifier (GA/GX/GY/GZ) when billing non‑covered services.